Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke

NCT00202020 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

720

Enrollment

INDUSTRY

Sponsor class

Conditions

Cerebral Infarction

Interventions

DRUG: Cilostazol 200mg/day Oral
DRUG: Aspirin 100mg/day Oral

Sponsor

Otsuka Beijing Research Institute

Collaborators

[object Object]